Display options
Cite
Iwama E, Fujimura T, Kusakari Y, et al. Multifocal BRAF(V600E)-Mutated Melanoma in situ on the Foot. Case Rep Dermatol. 2015;7(3):322-7doi: 10.1159/000441601.
Iwama, E., Fujimura, T., Kusakari, Y., Haga, T., & Aiba, S. (2015). Multifocal BRAF(V600E)-Mutated Melanoma in situ on the Foot. Case reports in dermatology, 7(3), 322-7. https://doi.org/10.1159/000441601
Iwama, Eimei, et al. "Multifocal BRAF(V600E)-Mutated Melanoma in situ on the Foot." Case reports in dermatology vol. 7,3 (2015): 322-7. doi: https://doi.org/10.1159/000441601
Iwama E, Fujimura T, Kusakari Y, Haga T, Aiba S. Multifocal BRAF(V600E)-Mutated Melanoma in situ on the Foot. Case Rep Dermatol. 2015 Oct 30;7(3):322-7. doi: 10.1159/000441601. eCollection 2015. PMID: 26594172; PMCID: PMC4650989.
Copy Download .nbib Format: NLM
Share it on

Case Rep Dermatol. 2015 Oct 30;7(3):322-7. doi: 10.1159/000441601. eCollection 2015.

Multifocal BRAF(V600E)-Mutated Melanoma in situ on the Foot.

Case reports in dermatology

Eimei Iwama, Taku Fujimura, Yoshiyuki Kusakari, Takahiro Haga, Setsuya Aiba

Affiliations

  1. Department of Dermatology, Tohoku University Graduate School of Medicine, Sendai, Japan.

PMID: 26594172 PMCID: PMC4650989 DOI: 10.1159/000441601

Abstract

Melanoma is an aggressive skin cancer that originates from melanocytes, and about one half of melanoma cases possess a BRAF mutation. Together with PD-L1 expression, the BRAF(V600E) mutation is one of the optimal therapeutic targets for the treatment of melanoma. In this report, we describe a case of multifocal melanoma in situ on the foot, which carried the p.V600E mutation in the BRAF gene. Interestingly, the spotted melanoma lesion is demarcated by normal skin, and in all spotted pigmented lesions, there were no signs of dermal invasion of melanoma cells or spontaneous regression. Our case presented atypical clinical features, which might correlate with the local mutations of BRAF gene and the immunological expression of PD-L1.

Keywords: BRAFV600E mutation; Malignant melanoma in situ; PD-L1

References

  1. J Invest Dermatol. 2012 Apr;132(4):1239-46 - PubMed
  2. Mol Cancer Ther. 2014 Dec;13(12):2769-83 - PubMed
  3. J Exp Med. 2006 Jul 10;203(7):1651-6 - PubMed
  4. Clin Cancer Res. 2012 Aug 15;18(16):4345-55 - PubMed
  5. Cancer Res. 2004 Aug 1;64(15):5456-60 - PubMed
  6. Dermatology. 2014;228(4):307-10 - PubMed
  7. Mol Cancer Ther. 2011 Mar;10(3):385-94 - PubMed
  8. Cancer Cell. 2011 Jan 18;19(1):11-5 - PubMed
  9. Nat Rev Drug Discov. 2012 Nov;11(11):873-86 - PubMed
  10. Cancer. 2010 Apr 1;116(7):1757-66 - PubMed
  11. J Cutan Pathol. 2011 Jun;38(6):514-20 - PubMed
  12. Clin Cancer Res. 2014 Oct 1;20(19):5064-74 - PubMed

Publication Types